key: cord-0061997-bqm8zsce
authors: Zhen, Wei; Berry, Gregory J.
title: Author’s Reply
date: 2021-04-16
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2021.04.001
sha: 0bcf864a64d01b843f7896b50908d485c3d7fbd8
doc_id: 61997
cord_uid: bqm8zsce

nan

the approach taken by Norz et al. is clearly one way to expedite the design, as well as the implementation of testing variants in many clinical laboratories through the utilization of both equipment and expertise that they already have. In addition, the use of previously published, peerreviewed assays that can identify the wild-type version of SARS-CoV-2 with high sensitivity and specificity, but have primer/probe designs that fall into the regions where mutations have now occurred in specific SARS-CoV-2 variants, facilitates rapid design because the assay has already been clinically- More notably, these variants share one or more additional mutations such as D614G, N501Y and E484K.

There is no doubt that this trend will continue and will also necessitate monitoring and re-design of assays in real-time to adjust to the changing viral landscape. As such, further studies are needed to continue to characterize these variants as they arise.

In summary, the modification of the NWHL LDT assay for use in identification of the HV69/70 deletion as Moving forward, this model describes a potential two-tier strategy, where variant information derived from whole genome sequencing surveillance programs continues to identify and characterize new variants, and then targeted molecular-based sensitive, accurate, and cost-effective diagnostic assays are developed to continue to monitor the prevalence and clinical significance of the identified circulating SAR-CoV-2 VOC.

Emergence of SARS-CoV-2 B.1.1.7 Lineage -United States

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature

RNA virus mutations and fitness for survival